A Rapid Shift in Treatment for Chronic Lymphocytic Leukemia - Episode 1

Risk Assessment in Newly Diagnosed CLL

Now Viewing
EP. 1: Risk Assessment in Newly Diagnosed CLL
EP. 2: Up-front Ibrutinib Versus FCR for Patients With CLL
EP. 3: Frontline Antibodies With BTK Inhibitors for CLL
EP. 4: Toxicities With BTK Inhibitors for CLL
EP. 5: Comparison of BTK Inhibitors for CLL
EP. 6: Obinutuzumab + Venetoclax for Frontline CLL
EP. 7: MRD Testing for CLL
EP. 8: Ibrutinib + Venetoclax for Frontline CLL
EP. 9: Resistance Mechanisms Associated With BTK Inhibitors
EP. 10: Progression on Frontline Ibrutinib in CLL
EP. 11: Venetoclax in R/R CLL
EP. 12: BTK Inhibitors in R/R CLL
EP. 13: PI3K Inhibitors in R/R CLL
EP. 14: Novel Combinations in Development for CLL
EP. 15: Final Thoughts From ASH 2019 in CLL